Hosted on MSN8d
Antibody-based therapy several notches closer to treat lethal mucormycosis: Study
Although both protect from infection, the humanized antibody reduces immunogenicity and enhances therapeutic effect when used ...
Medscape6d
Bivalent RSV Vaccine Shows Sustained Efficacy and Safety Through Two Seasons in Older Adults
The bivalent respiratory syncytial virus prefusion F vaccine is highly effective and well tolerated against RSV-associated ...
CDI Labs Launches Technology Access Program for Custom PhIP-Seq Libraries for Massively Multiplexed Analysis of Serum Antibodies
CDI Labs Canada Inc., a leading provider of services for proteome-wide antibody profiling and target identification, today ...
Center for Biosimilars6d
BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio
Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...
CURE6d
Global Submission Seeks Approval for Sugemalimab Treatment in NSCLC
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 ...
Pharmabiz5d
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer
CStone Pharma seeks EMA approval for sugemalimab to treat patients with unresectable stage III non-small cell lung cancer: Suzhou, China Tuesday, March 25, 2025, 17:00 Hrs [IST] C ...
health.economictimes.indiatimes7d
Antibody-based therapy several notches closer to treat lethal mucormycosis: Study
Although both protect from infection, the humanized antibody reduces immunogenicity and enhances therapeutic effect when used in humans, a major translational step. Early tests show that VX-01 is ...